Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Glenmark wins Russian...

    Glenmark wins Russian Health Ministry nod for allergic rhinitis drug Montlezir

    Farhat NasimWritten by Farhat Nasim Published On 2019-09-30T15:29:35+05:30  |  Updated On 30 Sept 2019 3:29 PM IST
    Glenmark wins Russian Health Ministry nod for allergic rhinitis drug Montlezir

    Glenmark Pharma's allergic rhinitis drug Montlezir is expected to be available in the Russian market in Q3 FY 2019‐20.


    Mumbai: Glenmark Pharmaceuticals Ltd., (Glenmark Pharma)today announced that it has received approval from the Ministry of Healthcare, Russia to market Montlezir (Levocetirizine Dihydrochloride 5mg + Montelukast Sodium 10mg) film‐coated tablets as a prescription product for the treatment of seasonal and perennial allergic rhinitis in patients above 15 years of age.


    Montlezir is expected to be available in the Russian market in Q3 FY 2019‐20.


    Commenting on the approval, Csaba Kantor, Senior Vice President and Head ‐ Asia, Russia & CIS region, Glenmark Pharmaceuticals, said, “Glenmark has built strong capabilities in the area of respiratory and is among the leading players in this therapy area across several markets globally. Russia is one of the key markets for us and we are consistently looking to expand our product portfolio. We believe that approval for Montlezir will help enhance our presence in this segment.”


    Also Read: Glenmark Pharma to raise Rs 1413 crore via debt securities


    “Allergic rhinitis affects a significant number of people in Russia, and we already have a number of products in our portfolio for the treatment of this condition. The approval to market Montlezir will further strengthen our company’s position in this segment and we are delighted to be able to bring new products to the market for patients suffering from this condition,” said Oxana Pozdnyakova, Vice President and Business Head – Russia, Glenmark Pharmaceuticals.


    According to IQVIA, Glenmark ranked 47th in the retail segment of the Russian pharmaceutical market as of MAT July 2019. In the respiratory space, Glenmark continues to secure a strong position and ranked 4th amongst the companies present in the expectorants market in Russia as of MAT July 2019. The company is ranked 10th in the retail dermatology market in the country.


    Also Read: Glenmark bags USFDA orphan drug status for antibody GBR 1342 to treat multiple myeloma

    allergic rhinitisallergy drugGlenmarkGlenmark PharmaHealthcareLevocetirizineMontelukastmontlezirpharmapharma newspharma news indiaRussiarussian health ministryRussian ministry

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok